Compare Eli Lilly And Co (LLY) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ServiceNow Inc — how do they compare? Eli Lilly And Co trades at $1,176.32 (market cap $1.04T), while ServiceNow Inc trades at $140.71 (market cap $144.48B). The key difference: Eli Lilly And Co is far larger — about 7.2× ServiceNow Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and ServiceNow Inc for 54 Days on average.
| LLY | NOW | |
|---|---|---|
Market Cap | $1.04T | $144.48B |
Volume | 3,064,878 | 11,801,699 |
Sector | Health | Technology |
52-Week High | $1.28K | $189.26 |
52-Week Low | $799.57 | $83.00 |
Typical Hold Time | 93 Days | 54 Days |
Enterprise Value | $1.09T | $148.27B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
ServiceNow (NOW) trades at $137.87, down slightly by 0.07% on the day. The stock shows strong fundamental momentum with revenue growing from $7.2B in 2022 to $13.3B in 2025 and consistent earnings beats in recent quarters. Technical indicators are bullish with the price above key moving averages, while analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $146.04 consensus target. The company's AI business has surpassed $1 billion in annual contract value, driving investor optimism.
ServiceNow presents a compelling growth story with robust AI adoption and expanding enterprise workflow solutions. The primary investment opportunity lies in the company's leadership position in enterprise AI and strong subscription revenue growth. Key risks include premium valuation multiples (P/E of 87.34), increasing competition in cloud software, and potential margin pressure as AI investments scale. The stock offers upside to analyst targets but requires monitoring of execution against ambitious growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
